<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357576</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00075458</org_study_id>
    <secondary_id>1R01FD005085-01A1</secondary_id>
    <nct_id>NCT02357576</nct_id>
  </id_info>
  <brief_title>Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD</brief_title>
  <official_title>Phase 3 Study of Standard Lipid Therapy Versus Intravenous Fat Emulsion Minimization for the Prevention of Parenteral Nutrition-Associated Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Primary Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parenteral nutrition-associated cholestasis (PNAC) and liver disease (PNALD) are associated
      with significant morbidity and mortality in neonates and is felt to be exacerbated by
      soybean-based lipid emulsions. Much research is currently being directed at identifying ways
      to reduce this risk. Reduction of the dose of soybean-based lipid given as a component of
      parenteral nutrition is one possible strategy. In this study we will compare standard dosing
      of soybean-based lipid (up to 3/kg/day) with a minimized dose (1 g/kg/day) and evaluate for
      the development of cholestasis and adequate growth between the two groups. Longterm followup
      will include an assessment of neurodevelopmental outcomes at 12 and 24 months of age.

      Funding source - FDA OOPD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2016</start_date>
  <completion_date type="Actual">November 8, 2019</completion_date>
  <primary_completion_date type="Actual">October 12, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Rise of Direct Bilirubin as a Function of Time</measure>
    <time_frame>12 weeks</time_frame>
    <description>The rate of rise (change over time) of direct bilirubin was compared between the two groups at different time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Parenteral Nutrition-associated Cholestasis (PNAC) (Direct Bilirubin ≥2 mg/dL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of participants who had a direct bilirubin ≥2 mg/dL were compared between the standard and reduced lipid groups. Bilirubin data was collected from baseline until 7 days after PN has been discontinued, but not to exceed a total of 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Severe Parenteral Nutrition-associated Cholestasis (PNAC) (Direct Bilirubin ≥4 mg/dL in Subjects on Parenteral Nutrition for at Least 2 Weeks)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of participants with severe PNAC defined as a direct bilirubin ≥4 mg/dL were compared between the standard and reduced lipid groups. Bilirubin data was collected from baseline until 7 days after PN has been discontinued, but not to exceed a total of 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time to Development of PNAC</measure>
    <time_frame>12 weeks</time_frame>
    <description>The time to development was compared between the standard and reduced lipid groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Time to Development of Severe PNAC</measure>
    <time_frame>12 weeks</time_frame>
    <description>The time to development from randomization was compared between the standard and reduced lipid groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Total Bilirubin Level</measure>
    <time_frame>12 weeks</time_frame>
    <description>The peak (highest) total bilirubin collected from each subject from after week 1 to end of treatment. This was compared between the standard and reduced lipid groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Direct Bilirubin Level</measure>
    <time_frame>12 weeks</time_frame>
    <description>The peak (highest) direct bilirubin collected from each subject from after week 1 to end of treatment. This was compared between the standard and reduced lipid groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Prevalence of Essential Fatty Acid Deficiency (EFAD)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of participants who experienced EFAD was compared between the standard and reduced lipid groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequacy of Growth as Evaluated by Z-scores for Weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Z-scores were compared between subjects in the two treatment groups by week. Z-scores are the number of standard deviations above (positive value) or below (negative value) the median on the FENTON and WHO growth charts. Fenton scores were used for infants born &lt;37 weeks gestation. WHO scores were used for infants born at ≥37 weeks gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequacy of Growth as Evaluated by Z-scores for Height</measure>
    <time_frame>12 weeks</time_frame>
    <description>Z-scores were compared between subjects in the two treatment groups. Z-scores are the number of standard deviations above (positive value) or below (negative value) the median on the FENTON and WHO growth charts. Fenton scores were used for infants born &lt;37 weeks gestation. WHO scores were used for infants born at ≥37 weeks gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequacy of Growth as Evaluated by Z-scores for Head Circumference</measure>
    <time_frame>12 weeks</time_frame>
    <description>Z-scores were compared between subjects in the two treatment groups. Z-scores are the number of standard deviations above (positive value) or below (negative value) the median on the FENTON and WHO growth charts. Fenton scores were used for infants born &lt;37 weeks gestation. WHO scores were used for infants born at ≥37 weeks gestation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events, as Defined by Any Episode of Sepsis and Catheter-related Blood Stream Infections</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of episodes were compared between the standard and reduced lipid groups of suspected sepsis episodes, NEC, or catheter-related blood stream infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bayley Scales for Infant and Toddler Development (BSID-III) at One Year</measure>
    <time_frame>1 year</time_frame>
    <description>The Bayley Scales of Infant and Toddler Development (BSID-III) is designed to assess developmental functioning of infants and toddlers, ages 1 month to 42 months. The instrument includes five distinct scales, of which three scales and associated subscales are utilized for the purposes of this study: cognitive, language (receptive and expressive communication) and motor (fine motor and gross motor). Raw scores are converted to scaled scores using age-standardized norm. The cognitive scaled scores range from 1-19. 1 is a low score and 19 is a high score. The Language scaled scores are calculated by adding the Receptive Communication scores ranging from 1-19 and the Expressive communication scores ranging from 1-19 to give the Language Scaled score of 2-38. The Motor scaled scores are calculated by adding the Fine Motor scores ranging from 1-19 and the Gross Motor scores ranging from 1-19 to give the Motor scaled ranging from 2-38. Higher scores are better than lower scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bayley Scales for Infant and Toddler Development (BSID-III) at Two Years</measure>
    <time_frame>2 years</time_frame>
    <description>Raw scores are converted to composite and subscale scores using age-standardized norms. Scale composite average internal consistency reliability coefficients range from .91 to .93 with subtest reliability ranging from .86 to .91.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MacArthur-Bates Communicative Development Inventories (CDI)</measure>
    <time_frame>2 years</time_frame>
    <description>Scores are reported as percentiles compared to age-standardized norms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Infant Toddler Social Emotional Assessment (BITSEA)</measure>
    <time_frame>2 years</time_frame>
    <description>Dichotomous scores are generated based on cut-off scores, which identify subjects to be at risk. Internal consistency coefficients range from.80 to.82. Test-retest reliability is acceptable at .80-.85. Recent evidence identifies the BITSEA as the best short tool for early detection of psychosocial problems in two-year olds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gross Motor Function Classification System (GMFCS)</measure>
    <time_frame>2 years</time_frame>
    <description>This classification is based on observation with a scale of 1-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Assessment System for Children-Second Edition (BASC2)</measure>
    <time_frame>2 years</time_frame>
    <description>Primary measurements from the BASC-2 including the Adaptive Behavior Composite and the Behavior Symptoms Index will be reported as T-scores and as percentiles. Secondary analyses will be conducted on the subscales.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Reduced Lipid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Lipid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid 20% I.V. Fat Emulsion</intervention_name>
    <arm_group_label>Reduced Lipid</arm_group_label>
    <arm_group_label>Standard Lipid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  neonates and infants who are at least 28 weeks corrected gestational age at the time
             of enrollment who are parenteral nutrition (PN) naive

          -  current direct bilirubin &lt;2 mg/dL

          -  any of the following conditions:

          -  meconium ileus and peritonitis

          -  gastroschisis

          -  omphalocele &gt;4cm or with liver herniated outside of the abdominal cavity

          -  necrotizing enterocolitis requiring surgical intervention

          -  volvulus

          -  intestinal atresia with &gt;50% bowel loss

        Exclusion Criteria:

          -  weight &lt;1 kg

          -  metabolic pathway defect which is associated with liver dysfunction in the neonatal
             period, including: hereditary fructose intolerance, galactosemia due to transferase
             deficiency and neonatal tyrosinemia, and/or disorder of lipid metabolism

          -  hepatic insufficiency as documented by either a biopsy with cirrhosis and/or marked
             aberration in synthetic function

          -  renal failure

          -  primary or secondary liver disease, regardless of liver function (includes hepatitis)

          -  use of extracorporeal membrane oxygenation (ECMO)

          -  suspected congenital obstruction of the hepatobiliary tree

          -  documented active infection which may be communicable, including infections hepatitis
             or HIV

          -  previous receipt of choleretic agents

          -  currently receiving phenobarbital or other barbiturates

          -  history of PNAC

          -  direct bilirubin &gt;=2 mg/dL at time of enrollment

          -  congenital or acquired anomaly which will require major cardiovascular surgery

          -  major congenital or chromosomal anomaly

          -  hypoxic ischemic encephalopathy

          -  congenital defect of the brain

          -  major seizure disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meghan A Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado/Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <results_first_submitted>December 23, 2019</results_first_submitted>
  <results_first_submitted_qc>January 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2020</results_first_posted>
  <disposition_first_submitted>March 13, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>March 13, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 22, 2019</disposition_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Meghan A. Arnold, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02357576/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients who were enrolled were randomized shortly after enrollment. 1 patient was removed immediately after enrollment, before intervention, due to a screen fail.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Reduced Lipid</title>
          <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
        </group>
        <group group_id="P2">
          <title>Standard Lipid</title>
          <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Neurodevelopmental Outcome Follow Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11">1 patient exited the study after treatment completion and before returning for follow up visits.</participants>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Scheduling error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Became ineligible during follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Reduced Lipid</title>
          <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
        </group>
        <group group_id="B2">
          <title>Standard Lipid</title>
          <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at randomization in TATUM</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B2" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B3" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Gastroschisis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intestinal atresia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Rise of Direct Bilirubin as a Function of Time</title>
        <description>The rate of rise (change over time) of direct bilirubin was compared between the two groups at different time points.</description>
        <time_frame>12 weeks</time_frame>
        <population>Analyzable data was not available for one participant in the Reduced Lipid Arm</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Rise of Direct Bilirubin as a Function of Time</title>
          <description>The rate of rise (change over time) of direct bilirubin was compared between the two groups at different time points.</description>
          <population>Analyzable data was not available for one participant in the Reduced Lipid Arm</population>
          <units>mg/dL/day</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Day from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.033001353" lower_limit="1.011427197" upper_limit="1.055035694"/>
                    <measurement group_id="O2" value="1.05457485" lower_limit="1.029533513" upper_limit="1.080225375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 Days from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.025504411" lower_limit="1.005132124" upper_limit="1.046289609"/>
                    <measurement group_id="O2" value="1.049318179" lower_limit="1.025241711" upper_limit="1.07396016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Days from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.999691048" lower_limit="0.981391909" upper_limit="1.018331496"/>
                    <measurement group_id="O2" value="1.031125269" lower_limit="1.008439715" upper_limit="1.05432115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>56 Days from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96628119" lower_limit="0.945472667" upper_limit="0.987547779"/>
                    <measurement group_id="O2" value="1.007357736" lower_limit="0.981844238" upper_limit="1.033534209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>84 Days from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.933987896" lower_limit="0.907126199" upper_limit="0.961645019"/>
                    <measurement group_id="O2" value="0.984138047" lower_limit="0.952398442" upper_limit="1.016935507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Parenteral Nutrition-associated Cholestasis (PNAC) (Direct Bilirubin ≥2 mg/dL)</title>
        <description>The number of participants who had a direct bilirubin ≥2 mg/dL were compared between the standard and reduced lipid groups. Bilirubin data was collected from baseline until 7 days after PN has been discontinued, but not to exceed a total of 12 weeks.</description>
        <time_frame>12 weeks</time_frame>
        <population>Analyzable data was not available for one participant in the Reduced Lipid Arm</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Parenteral Nutrition-associated Cholestasis (PNAC) (Direct Bilirubin ≥2 mg/dL)</title>
          <description>The number of participants who had a direct bilirubin ≥2 mg/dL were compared between the standard and reduced lipid groups. Bilirubin data was collected from baseline until 7 days after PN has been discontinued, but not to exceed a total of 12 weeks.</description>
          <population>Analyzable data was not available for one participant in the Reduced Lipid Arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Percentage and frequencies were used to describe the incidence of PNAC in the two groups.</non_inferiority_desc>
            <p_value>0.617</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Severe Parenteral Nutrition-associated Cholestasis (PNAC) (Direct Bilirubin ≥4 mg/dL in Subjects on Parenteral Nutrition for at Least 2 Weeks)</title>
        <description>The number of participants with severe PNAC defined as a direct bilirubin ≥4 mg/dL were compared between the standard and reduced lipid groups. Bilirubin data was collected from baseline until 7 days after PN has been discontinued, but not to exceed a total of 12 weeks.</description>
        <time_frame>12 weeks</time_frame>
        <population>Analyzable data was not available for one participant in the Reduced Lipid Arm</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Severe Parenteral Nutrition-associated Cholestasis (PNAC) (Direct Bilirubin ≥4 mg/dL in Subjects on Parenteral Nutrition for at Least 2 Weeks)</title>
          <description>The number of participants with severe PNAC defined as a direct bilirubin ≥4 mg/dL were compared between the standard and reduced lipid groups. Bilirubin data was collected from baseline until 7 days after PN has been discontinued, but not to exceed a total of 12 weeks.</description>
          <population>Analyzable data was not available for one participant in the Reduced Lipid Arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Percentage and frequencies were used to describe the incidence of severe PNAC.</non_inferiority_desc>
            <p_value>0.450</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time to Development of PNAC</title>
        <description>The time to development was compared between the standard and reduced lipid groups.</description>
        <time_frame>12 weeks</time_frame>
        <population>Only the subjects that developed PNAC were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Development of PNAC</title>
          <description>The time to development was compared between the standard and reduced lipid groups.</description>
          <population>Only the subjects that developed PNAC were analyzed</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.50" lower_limit="14" upper_limit="25"/>
                    <measurement group_id="O2" value="39.00" lower_limit="29" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The Kaplan Meier curve was used to evaluated the time to first PNAC event.</non_inferiority_desc>
            <p_value>0.2716</p_value>
            <method>Log Rank</method>
            <method_desc>A log rank test was used to test the equality of the survival curve between the two groups.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Time to Development of Severe PNAC</title>
        <description>The time to development from randomization was compared between the standard and reduced lipid groups.</description>
        <time_frame>12 weeks</time_frame>
        <population>Subjects who developed severe PNAC as defined by a direct bilirubin value of 4 mg/dL or greater</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Development of Severe PNAC</title>
          <description>The time to development from randomization was compared between the standard and reduced lipid groups.</description>
          <population>Subjects who developed severe PNAC as defined by a direct bilirubin value of 4 mg/dL or greater</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Total Bilirubin Level</title>
        <description>The peak (highest) total bilirubin collected from each subject from after week 1 to end of treatment. This was compared between the standard and reduced lipid groups.</description>
        <time_frame>12 weeks</time_frame>
        <population>Subjects with total bilirubin values collected after 1 week</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Total Bilirubin Level</title>
          <description>The peak (highest) total bilirubin collected from each subject from after week 1 to end of treatment. This was compared between the standard and reduced lipid groups.</description>
          <population>Subjects with total bilirubin values collected after 1 week</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.2" upper_limit="9.9"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.7" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Direct Bilirubin Level</title>
        <description>The peak (highest) direct bilirubin collected from each subject from after week 1 to end of treatment. This was compared between the standard and reduced lipid groups.</description>
        <time_frame>12 weeks</time_frame>
        <population>Subjects with direct bilirubin values collected after 1 week</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Direct Bilirubin Level</title>
          <description>The peak (highest) direct bilirubin collected from each subject from after week 1 to end of treatment. This was compared between the standard and reduced lipid groups.</description>
          <population>Subjects with direct bilirubin values collected after 1 week</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.3" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.6" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Prevalence of Essential Fatty Acid Deficiency (EFAD)</title>
        <description>The number of participants who experienced EFAD was compared between the standard and reduced lipid groups.</description>
        <time_frame>12 weeks</time_frame>
        <population>All patients in the reduced lipid group were analyzed. The standard lipid group had essential fatty acid profile drawn for one patient as not all patients in the standard group required the essential fatty acid profile to be drawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>The Prevalence of Essential Fatty Acid Deficiency (EFAD)</title>
          <description>The number of participants who experienced EFAD was compared between the standard and reduced lipid groups.</description>
          <population>All patients in the reduced lipid group were analyzed. The standard lipid group had essential fatty acid profile drawn for one patient as not all patients in the standard group required the essential fatty acid profile to be drawn.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adequacy of Growth as Evaluated by Z-scores for Weight</title>
        <description>Z-scores were compared between subjects in the two treatment groups by week. Z-scores are the number of standard deviations above (positive value) or below (negative value) the median on the FENTON and WHO growth charts. Fenton scores were used for infants born &lt;37 weeks gestation. WHO scores were used for infants born at ≥37 weeks gestation.</description>
        <time_frame>12 weeks</time_frame>
        <population>All subjects aside from the screen fail. Z-scores were recorded while subjects were &quot;on treatment&quot; which meant that they were recorded until 7 days after parenteral nutrition (PN) had been discontinued, but not to exceed 12 weeks for subjects still on PN. This is why the participants analyzed each week is a different number and decreasing with time</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Adequacy of Growth as Evaluated by Z-scores for Weight</title>
          <description>Z-scores were compared between subjects in the two treatment groups by week. Z-scores are the number of standard deviations above (positive value) or below (negative value) the median on the FENTON and WHO growth charts. Fenton scores were used for infants born &lt;37 weeks gestation. WHO scores were used for infants born at ≥37 weeks gestation.</description>
          <population>All subjects aside from the screen fail. Z-scores were recorded while subjects were &quot;on treatment&quot; which meant that they were recorded until 7 days after parenteral nutrition (PN) had been discontinued, but not to exceed 12 weeks for subjects still on PN. This is why the participants analyzed each week is a different number and decreasing with time</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Birth</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" lower_limit="-3.14" upper_limit="0.47"/>
                    <measurement group_id="O2" value="-0.93" lower_limit="-1.71" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" lower_limit="-3.46" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="-1.85" lower_limit="-2.26" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" lower_limit="-3.49" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-2.38" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" lower_limit="-3.73" upper_limit="-0.59"/>
                    <measurement group_id="O2" value="-1.485" lower_limit="-2.47" upper_limit="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.575" lower_limit="-3.61" upper_limit="-0.84"/>
                    <measurement group_id="O2" value="-1.59" lower_limit="-2.01" upper_limit="-1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" lower_limit="-3.52" upper_limit="-0.44"/>
                    <measurement group_id="O2" value="-1.78" lower_limit="-2.34" upper_limit="-1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" lower_limit="-3.81" upper_limit="-0.55"/>
                    <measurement group_id="O2" value="-1.88" lower_limit="-2.49" upper_limit="-0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" lower_limit="-3.48" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-1.62" lower_limit="-2.53" upper_limit="-0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" lower_limit="-2.66" upper_limit="-0.55"/>
                    <measurement group_id="O2" value="-1.745" lower_limit="-2.68" upper_limit="-0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" lower_limit="-2.38" upper_limit="-0.41"/>
                    <measurement group_id="O2" value="-1.745" lower_limit="-2.46" upper_limit="-1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.415" lower_limit="-2.44" upper_limit="-0.39"/>
                    <measurement group_id="O2" value="-1.785" lower_limit="-2.55" upper_limit="-1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.355" lower_limit="-2.31" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="-1.885" lower_limit="-2.41" upper_limit="-1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" lower_limit="-2.36" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="-1.885" lower_limit="-2.56" upper_limit="-1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adequacy of Growth as Evaluated by Z-scores for Height</title>
        <description>Z-scores were compared between subjects in the two treatment groups. Z-scores are the number of standard deviations above (positive value) or below (negative value) the median on the FENTON and WHO growth charts. Fenton scores were used for infants born &lt;37 weeks gestation. WHO scores were used for infants born at ≥37 weeks gestation.</description>
        <time_frame>12 weeks</time_frame>
        <population>All subjects aside from the screen fail. Z-scores were recorded while subjects were &quot;on treatment&quot; which meant that they were recorded until 7 days after parenteral nutrition (PN) had been discontinued, but not to exceed 12 weeks for subjects still on PN. This is why the participants analyzed each week is a different number and decreasing with time</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Adequacy of Growth as Evaluated by Z-scores for Height</title>
          <description>Z-scores were compared between subjects in the two treatment groups. Z-scores are the number of standard deviations above (positive value) or below (negative value) the median on the FENTON and WHO growth charts. Fenton scores were used for infants born &lt;37 weeks gestation. WHO scores were used for infants born at ≥37 weeks gestation.</description>
          <population>All subjects aside from the screen fail. Z-scores were recorded while subjects were &quot;on treatment&quot; which meant that they were recorded until 7 days after parenteral nutrition (PN) had been discontinued, but not to exceed 12 weeks for subjects still on PN. This is why the participants analyzed each week is a different number and decreasing with time</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Birth</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" lower_limit="-3.84" upper_limit="0.29"/>
                    <measurement group_id="O2" value="-0.87" lower_limit="-2.62" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.365" lower_limit="-4.41" upper_limit="0"/>
                    <measurement group_id="O2" value="-1.22" lower_limit="-3.2" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" lower_limit="-4.22" upper_limit="-0.58"/>
                    <measurement group_id="O2" value="-1.55" lower_limit="-3.73" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" lower_limit="-4.77" upper_limit="-0.65"/>
                    <measurement group_id="O2" value="-1.775" lower_limit="-2.57" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" lower_limit="-4.6" upper_limit="-0.56"/>
                    <measurement group_id="O2" value="-1.91" lower_limit="-2.72" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.21" lower_limit="-4.57" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-2.11" lower_limit="-3.25" upper_limit="-1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" lower_limit="-4.52" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-2.37" lower_limit="-3.25" upper_limit="-1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" lower_limit="-3.37" upper_limit="-0.98"/>
                    <measurement group_id="O2" value="-2.39" lower_limit="-3.47" upper_limit="-1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" lower_limit="-1.71" upper_limit="2.93"/>
                    <measurement group_id="O2" value="-2.51" lower_limit="-3.29" upper_limit="-1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" lower_limit="-2.1" upper_limit="-0.45"/>
                    <measurement group_id="O2" value="-2.865" lower_limit="-3.37" upper_limit="-2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" lower_limit="-2.47" upper_limit="-0.69"/>
                    <measurement group_id="O2" value="-2.62" lower_limit="-3.3" upper_limit="-1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" lower_limit="-2.83" upper_limit="-1.05"/>
                    <measurement group_id="O2" value="-2.81" lower_limit="-3.59" upper_limit="-2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.935" lower_limit="-1.7" upper_limit="-0.17"/>
                    <measurement group_id="O2" value="-2.775" lower_limit="-3.19" upper_limit="-2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adequacy of Growth as Evaluated by Z-scores for Head Circumference</title>
        <description>Z-scores were compared between subjects in the two treatment groups. Z-scores are the number of standard deviations above (positive value) or below (negative value) the median on the FENTON and WHO growth charts. Fenton scores were used for infants born &lt;37 weeks gestation. WHO scores were used for infants born at ≥37 weeks gestation.</description>
        <time_frame>12 weeks</time_frame>
        <population>All subjects aside from the screen fail. Z-scores were recorded while subjects were &quot;on treatment&quot; which meant that they were recorded until 7 days after parenteral nutrition (PN) had been discontinued, but not to exceed 12 weeks for subjects still on PN. This is why the participants analyzed each week is a different number and decreasing with time</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Adequacy of Growth as Evaluated by Z-scores for Head Circumference</title>
          <description>Z-scores were compared between subjects in the two treatment groups. Z-scores are the number of standard deviations above (positive value) or below (negative value) the median on the FENTON and WHO growth charts. Fenton scores were used for infants born &lt;37 weeks gestation. WHO scores were used for infants born at ≥37 weeks gestation.</description>
          <population>All subjects aside from the screen fail. Z-scores were recorded while subjects were &quot;on treatment&quot; which meant that they were recorded until 7 days after parenteral nutrition (PN) had been discontinued, but not to exceed 12 weeks for subjects still on PN. This is why the participants analyzed each week is a different number and decreasing with time</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Birth</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" lower_limit="-4.12" upper_limit="0.82"/>
                    <measurement group_id="O2" value="-0.94" lower_limit="-1.65" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" lower_limit="-3.8" upper_limit="0.25"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-1.83" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" lower_limit="-3.91" upper_limit="0.04"/>
                    <measurement group_id="O2" value="-0.82" lower_limit="-2.31" upper_limit="-0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" lower_limit="-3.66" upper_limit="-0.03"/>
                    <measurement group_id="O2" value="-1" lower_limit="-1.58" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.745" lower_limit="-2.74" upper_limit="-0.81"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-1.45" upper_limit="-0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.225" lower_limit="-2.81" upper_limit="0.15"/>
                    <measurement group_id="O2" value="-1.38" lower_limit="-1.41" upper_limit="-1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" lower_limit="-2.77" upper_limit="0.23"/>
                    <measurement group_id="O2" value="-1.56" lower_limit="-1.74" upper_limit="-1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" lower_limit="-1.6" upper_limit="-0.12"/>
                    <measurement group_id="O2" value="-1.095" lower_limit="-1.25" upper_limit="-0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.845" lower_limit="-1.17" upper_limit="-0.08"/>
                    <measurement group_id="O2" value="-1.455" lower_limit="-1.61" upper_limit="-1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" lower_limit="-1.49" upper_limit="-0.24"/>
                    <measurement group_id="O2" value="-1.39" lower_limit="-1.51" upper_limit="-1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" lower_limit="-1.75" upper_limit="0.07"/>
                    <measurement group_id="O2" value="-1.255" lower_limit="-1.35" upper_limit="-1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.935" lower_limit="-2.05" upper_limit="0.18"/>
                    <measurement group_id="O2" value="-1.19" lower_limit="-1.19" upper_limit="-1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" lower_limit="-1.15" upper_limit="-0.11"/>
                    <measurement group_id="O2" value="-1.31" lower_limit="-1.88" upper_limit="-0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events, as Defined by Any Episode of Sepsis and Catheter-related Blood Stream Infections</title>
        <description>The number of episodes were compared between the standard and reduced lipid groups of suspected sepsis episodes, NEC, or catheter-related blood stream infections.</description>
        <time_frame>12 weeks</time_frame>
        <population>Subjects who experienced an episode of suspected sepsis, catheter-related blood stream infection, or NEC</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events, as Defined by Any Episode of Sepsis and Catheter-related Blood Stream Infections</title>
          <description>The number of episodes were compared between the standard and reduced lipid groups of suspected sepsis episodes, NEC, or catheter-related blood stream infections.</description>
          <population>Subjects who experienced an episode of suspected sepsis, catheter-related blood stream infection, or NEC</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participant 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bayley Scales for Infant and Toddler Development (BSID-III) at One Year</title>
        <description>The Bayley Scales of Infant and Toddler Development (BSID-III) is designed to assess developmental functioning of infants and toddlers, ages 1 month to 42 months. The instrument includes five distinct scales, of which three scales and associated subscales are utilized for the purposes of this study: cognitive, language (receptive and expressive communication) and motor (fine motor and gross motor). Raw scores are converted to scaled scores using age-standardized norm. The cognitive scaled scores range from 1-19. 1 is a low score and 19 is a high score. The Language scaled scores are calculated by adding the Receptive Communication scores ranging from 1-19 and the Expressive communication scores ranging from 1-19 to give the Language Scaled score of 2-38. The Motor scaled scores are calculated by adding the Fine Motor scores ranging from 1-19 and the Gross Motor scores ranging from 1-19 to give the Motor scaled ranging from 2-38. Higher scores are better than lower scores.</description>
        <time_frame>1 year</time_frame>
        <population>Participants who returned for their one year follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Lipid</title>
            <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
          <group group_id="O2">
            <title>Standard Lipid</title>
            <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
          </group>
        </group_list>
        <measure>
          <title>Bayley Scales for Infant and Toddler Development (BSID-III) at One Year</title>
          <description>The Bayley Scales of Infant and Toddler Development (BSID-III) is designed to assess developmental functioning of infants and toddlers, ages 1 month to 42 months. The instrument includes five distinct scales, of which three scales and associated subscales are utilized for the purposes of this study: cognitive, language (receptive and expressive communication) and motor (fine motor and gross motor). Raw scores are converted to scaled scores using age-standardized norm. The cognitive scaled scores range from 1-19. 1 is a low score and 19 is a high score. The Language scaled scores are calculated by adding the Receptive Communication scores ranging from 1-19 and the Expressive communication scores ranging from 1-19 to give the Language Scaled score of 2-38. The Motor scaled scores are calculated by adding the Fine Motor scores ranging from 1-19 and the Gross Motor scores ranging from 1-19 to give the Motor scaled ranging from 2-38. Higher scores are better than lower scores.</description>
          <population>Participants who returned for their one year follow up</population>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cognitive Scaled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="14"/>
                    <measurement group_id="O2" value="10" lower_limit="9" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Language Scaled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="20"/>
                    <measurement group_id="O2" value="16" lower_limit="13" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motor Scaled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="15" upper_limit="20"/>
                    <measurement group_id="O2" value="20" lower_limit="12" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bayley Scales for Infant and Toddler Development (BSID-III) at Two Years</title>
        <description>Raw scores are converted to composite and subscale scores using age-standardized norms. Scale composite average internal consistency reliability coefficients range from .91 to .93 with subtest reliability ranging from .86 to .91.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MacArthur-Bates Communicative Development Inventories (CDI)</title>
        <description>Scores are reported as percentiles compared to age-standardized norms.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Infant Toddler Social Emotional Assessment (BITSEA)</title>
        <description>Dichotomous scores are generated based on cut-off scores, which identify subjects to be at risk. Internal consistency coefficients range from.80 to.82. Test-retest reliability is acceptable at .80-.85. Recent evidence identifies the BITSEA as the best short tool for early detection of psychosocial problems in two-year olds.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gross Motor Function Classification System (GMFCS)</title>
        <description>This classification is based on observation with a scale of 1-5</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Behavioral Assessment System for Children-Second Edition (BASC2)</title>
        <description>Primary measurements from the BASC-2 including the Adaptive Behavior Composite and the Behavior Symptoms Index will be reported as T-scores and as percentiles. Secondary analyses will be conducted on the subscales.</description>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Reduced Lipid</title>
          <description>Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
        </group>
        <group group_id="E2">
          <title>Standard Lipid</title>
          <description>Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
Intralipid 20% I.V. Fat Emulsion</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia- Serious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ischemic Bowel Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Intestinal Failure- Short Bowel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Inadequate Weight Gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis- normal anion gap and bicarbonate loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>PNAC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Necrotizing enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Acute respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PICC associated DVT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia with Tachypnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Non-severe Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Inadequate weight gain- non-severe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral Thrush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Line Complication, Removal, or Replacement</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There was a smaller sample size than expected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Meghan Arnold</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-936-8978</phone>
      <email>meghanar@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

